pain-management-2018-scientifictracks

5 / 31

Page 47
Notes:
conferenceseries.com
Volume 7 Journal of Pain & Relief
ISSN: 2167-0846 Pain Management 2018
October 11-12, 2018
October 11-12, 2018 | Zurich, Switzerland
7th International Conference and Exhibition on
Pain Research and Management
3. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. (2017 ) A
Controlled Trial of Erenumab for Episodic Migraine. The New England Journal of Medicine. 377(22): 2123.
4. Seidel MF, Wise BL, Lane NE. (2013) Nerve growth factor: an update on the science and therapy. Osteoarthritis Cartilage
21(9): 1223.
5. Tiseo PJ, Kivitz AJ, Ervin JE, Ren H, Mellis SJ. (2014) Fasinumab (REGN475), an antibody against nerve growth factor
for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee.
Pain 155(7): 1245.
Biography
Matthias Seidel has obtained his graduate medical and neuroscience training in Italy, Germany and the United States. He received his medical degree in Essen (Germany)
and then served as a Marie-Curie-Fellow in Créteil (Paris/France). He is licensed in Internal Medicine and Rheumatology and has worked in several rheumatology
departments in Bonn (Germany), Basel and Biel/Bienne (both Switzerland) where he was recently appointed a chief position. His major scientific interests are neurogenic
inflammation in clinical medicine, biomarker molecules and rare diseases in rheumatology.